HIV-1 and HIV-2 Antibodies for Cadaveric or Hemolyzed Specimens, Serum
Use
This test is useful for diagnosing HIV-1 and/or HIV-2 infection in cadaveric or hemolyzed serum specimens from symptomatic patients with or without risk factors for HIV infection. It begins with an HIV-1/-2 antibody enzyme immunoassay (EIA). If reactive, HIV antibody confirmation/differentiation by immunochromatographic method is performed at an additional charge. However, this test is not intended for screening or confirmatory testing for blood donor specimens.
Special Instructions
Not provided.
Limitations
Antibodies against HIV-1 and HIV-2 are usually not detected until 6 to 12 weeks following exposure and are almost always detected by 12 months. The predictive value of a reactive test is highly dependent on the prevalence of infection in the population tested, with a lower prevalence leading to a lower positive predictive value. The test cannot distinguish between active neonatal HIV infection and passive transfer of maternal HIV antibodies in infants up to 2 years of age. Confirmatory testing is recommended for rapid test-reactive but EIA negative specimens.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 31201-7 - HIV1+2 Ab SerPl Ql IA
- 31201-7 - HIV1+2 Ab SerPl Ql IA
Result Turnaround Time
1-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.5 mL
Minimum Volume
0.2 mL
Container
Plastic vial
Collection Instructions
Centrifuge blood collection tube per collection tube manufacturer's instructions (e.g., within 2 hours of collection for BD Vacutainer tubes). Aliquot serum into a plastic vial.
Causes for Rejection
Gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
| Frozen | 30 days |